Cash/Burn From SEC Filing For Period: 

Q3 '19

KRTX

Karuna Therapeutics

We are an innovative clinical-stage biopharmaceutical company primarily focused on developing novel therapies to address disabling neuropsychiatric conditions characterized by significant unmet medical need.

Cash

$54.1M

Burn Rate

$9.0M

Amp Analysis

Pipeline Information

Click drug data to see upcoming trial info and prior data

Drug | Disease

Stage | Exp Date

Prior Data

KarXT

Schizophrenia Psychosis

End Phase 2 Meeting (possible BTD)

2Q '20

KarXT

Schizophrenia Negative Symptoms

Phase 1b TBA

1H '20

KarXT

Schizophrenia Cognitive Symptoms

Phase 1b TBA

1H '20

KarXT

Pain

Phase 1b

Mid 2020

KarXT

Dementia Related Psychosis

Phase 1b

2H '20

Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

PROUDLY CREATED WITH WIX.COM

  • Twitter Social Icon
  • LinkedIn Social Icon